Rabizadeh, E. published the artcileDoxorubicin and a butyric acid derivative effectively reduce levels of bcl-2 protein in the cells of chronic lymphocytic leukemia patient, Safety of (Pivaloyloxy)methyl butyrate, the publication is European Journal of Haematology (2001), 66(4), 263-271, database is CAplus and MEDLINE.
B-chronic lymphocytic leukemia (B-CLL) is a disease caused primarily by defects in the apoptosis mechanism. AN-9, a butyric acid (BA) derivative, is a potent differentiating and an anti-cancer drug that induces apoptosis in HL-60 cells. Herein the authors show the effect of AN-9, alone and in combination with doxorubicin, on cell cultures from B-CLL patients. Cells from 17 patients were cultured and tested for viability, apoptosis, bcl-2, and Bax protein expression. Exposure of B-CLL cell cultures to AN-9 was accompanied by apoptosis and a marked viability loss (up to 46%, p=0.0017). AN-9 reduced up to 51% (p=0.0017) the levels of bcl-2 in 57% of the cultures that express bcl-2. The combination of low concentrations of AN-9 and doxorubicin more than additively enhanced apoptosis and reduced bcl-2 levels in B-CLL cultures which were resistant to AN-9. AN-9 enhanced Bax expression up to 58% (p=0.008) in cultures from 53% of the patients but had no effect on Bax levels when combined with doxorubicin. In conclusion, AN-9 alone reduced bcl-2 and enhanced Bax expression in cultures from B-CLL patients, and the reduction of bcl-2 levels in combination with doxorubicin was greater than additive. These results may be beneficial in possible future combination therapy with AN-9 in B-CLL.
European Journal of Haematology published new progress about 122110-53-6. 122110-53-6 belongs to esters-buliding-blocks, auxiliary class Aliphatic hydrocarbon chain,Ester,Inhibitor, name is (Pivaloyloxy)methyl butyrate, and the molecular formula is C10H18O4, Safety of (Pivaloyloxy)methyl butyrate.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics